Autoimmune diseases

Allogene's Dual-Acting CAR T Candidate ALLO-329...
CMN Clinical

Jan. 29, 2025

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...

Autoimmune diseases

Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Lupus Nephritis, (NCT06681337)
Sponsors:
Bioray Laboratories
Indicator
IND Enabling
Phase I
Phase II
Phase III
Neuromyelitis Optica Spectrum Disease, NMOSD, (NCT06633042)
Sponsors:
Bioray Laboratories
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06373991)
Sponsors:
EdiGene Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Refractory Autoimmune Diseases, (NCT06485232)
Sponsors:
Xuanwu Hospital, Beijing
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT05988216)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Autoimmune Diseases, (NCT05859997)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine